China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions is set to establish a bio-industry park in Slovenia, marking a significant expansion of its presence in the European market. The project will involve an investment of EUR 50 million (USD 54.2 million) and will include the construction of an active ingredient manufacturing plant, several laboratories, and facilities for clinical-trial scale production.
Details of the Investment
The bio-industry park in Slovenia will serve as Porton’s first major manufacturing and development site in Europe, complementing its existing sales units in Belgium and Switzerland. The investment underscores Porton’s commitment to enhancing its capabilities and market reach on the continent. The project is expected to create new opportunities for collaboration and innovation in the European biopharmaceutical sector.
Partnership with Novartis
Porton Pharma Solutions is a key supplier to Novartis, and the Swiss pharmaceutical giant will reportedly lease Porton some of its existing facilities in the town of Menges, Slovenia. This strategic move could further deepen the relationship between Porton and Novartis, given that Novartis owns and operates the Slovenian generics-focused firm Lek, which falls under the Sandoz umbrella. The collaboration is expected to enhance Porton’s operational efficiency and strengthen its position as a leading CDMO in the global market.
Future Outlook
The establishment of the bio-industry park in Slovenia represents a strategic step for Porton Pharma Solutions as it seeks to expand its footprint in Europe. With strong partnerships and significant investment, Porton is poised to play a more prominent role in the development and manufacturing of biopharmaceuticals. The collaboration with Novartis further solidifies Porton’s position as a reliable partner in the industry, paving the way for future growth and innovation.-Fineline Info & Tech
